SOURCE: Oragenics, Inc.

December 05, 2007 11:46 ET

Oragenics, Inc. Selects Qualia Clinical Services to Conduct SMaRT™ Phase 1 Trial

ALACHUA, FL--(Marketwire - December 5, 2007) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company focused on infectious diseases and cancer, announced today that Qualia Clinical Services, located in Omaha, Nebraska, has been selected to provide clinical site services for the Company's recently approved Phase 1b safety trial. The trial will be conducted in compliance with the approved FDA protocol and is designed to evaluate the safety and tolerability of the Company's SMaRT Replacement Therapy™ in healthy, adult male subjects over a six-week period, with a long-term follow-up evaluation at six months.

Dr. Robert Zahradnik, the Company's President and CEO, stated, "Certainly, initiation of this Phase 1b safety study is an important milestone for us. But this study also represents an important milestone for advancing clinical knowledge regarding the replacement therapy concept as a means for treating or preventing bacterial infections. We are pleased to be partnering with Qualia Clinical Services, a recognized leader in the clinical services industry." SMaRT Replacement Therapy for the prevention of dental cavities was developed by Oragenics' Chief Scientific Officer, Dr. Jeffrey Hillman, using recombinant DNA techniques to generate the current Streptococcus mutans replacement strain, A2JM. Subject enrollment for the Phase 1b clinical trial is anticipated to begin in early 2008.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and weight loss. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

About Qualia Clinical Services

Qualia Clinical Services is changing lives for the better by providing its partners in the clinical research industry with the absolute best in complete early and late phase capabilities, bioanalytical support, and data management services. A full service contract research organization, Qualia has state-of-the-art clinical operations in Omaha, Nebraska, Toronto, Canada and Kiev, Ukraine. With our network of facilities and partners around the world, we are able to manage virtually every aspect of clinical research.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact Information